 CymaBay Therapeutics NASDAQ:CBAYs stock had its buy rating restated by research analysts at B. Riley in a research report issued on Monday, TipRanks reports. They currently have a 6.00 price objective on the biopharmaceutical companys stock. B. Rileys price objective points to a potential upside of 52.28 from the companys current price. CBAY has been ... 